Supernus Pharm (SUPN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 184,869 | 128,448 | 151,371 | 144,711 | 115,848 |
| Marketable Securities | 199,372 | 180,222 | 129,789 | 377,885 | 347,742 |
| Receivables | 182,183 | 187,802 | 171,254 | 140,831 | 145,640 |
| Inventories | 87,062 | 82,385 | 79,399 | 44,023 | 49,423 |
| TOTAL | $731,580 | $644,182 | $593,891 | $738,866 | $687,584 |
| Non-Current Assets | |||||
| PPE Net | 10,042 | 10,531 | 10,627 | 11,069 | 11,338 |
| Intangibles | 670,380 | 694,338 | 742,561 | 598,326 | 619,145 |
| Other Non-Current Assets | 88,723 | 103,597 | 72,675 | 34,144 | 29,223 |
| TOTAL | $769,145 | $808,466 | $825,863 | $643,539 | $659,706 |
| Total Assets | $1,500,725 | $1,452,648 | $1,419,754 | $1,382,405 | $1,347,290 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 101,244 | 107,800 | 108,613 | 77,739 | 76,891 |
| Accrued Expenses | 189,720 | 161,097 | 184,459 | 180,916 | 170,133 |
| Other current liabilities | 82,965 | 69,274 | 37,557 | 27,705 | 34,748 |
| TOTAL | $373,929 | $338,171 | $330,629 | $286,360 | $281,772 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 49,991 | 52,763 | 39,458 | 32,145 | 33,832 |
| TOTAL | $49,991 | $52,763 | $39,458 | $32,145 | $34,813 |
| Total Liabilities | $423,920 | $390,934 | $370,087 | $318,505 | $316,585 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 58,040 | 57,582 | 57,339 | 56,073 | 55,990 |
| Common Shares | 58 | 57 | 57 | 56 | 56 |
| Retained earnings | 515,583 | 517,876 | 521,981 | 567,098 | 544,599 |
| Other shareholders' equity | -255 | -44 | -71 | -200 | -159 |
| TOTAL | $1,076,805 | $1,061,714 | $1,049,667 | $1,063,900 | $1,030,705 |
| Total Liabilities And Equity | $1,500,725 | $1,452,648 | $1,419,754 | $1,382,405 | $1,347,290 |